Juliet Preston
Juliet Preston is a freelance writer based in San Diego.
-
Connecting the dots between rapid sepsis diagnosis, patient outcomes, and healthcare costs
T2 Biosystems’ novel MRI-based platform for diagnosing invasive candida infections is fast and accurate. Does that automatically translate to lower hospital costs?
-
This AI screening tool for diabetic retinopathy makes a decision, not a recommendation
The system has an artificial intelligence algorithm that evaluates the images coming from the camera and determines whether or not there’s diabetic retinopathy in them,” explained IDx Founder and President Michael Abràmoff. “So it makes a clinical decision, without someone like me being involved — it’s fully autonomous.”
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Stanford spin-out Zenflow raises $31M to join the megamarket for enlarged prostate
Y Combinator graduate Zenflow has raised a $31.4 million Series A following a successful human trial of its Spring System in patients with benign prostatic hyperplasia (BPH) or enlarged prostate.
-
Capitalizing on a gene therapy boom, Avrobio locks in $60M
Avrobio has secured $60 million in new financing on the back of its first successful gene therapy trial in a patient with Fabry disease.
-
After 18 years, will vTv Therapeutics’ Alzheimer’s drug sink or swim?
vTv Therapeutics has spent nearly two decades advancing its Alzheimer’s drug, and results from two Phase 3 trials are expected in 2018.
-
Anatomy of two biotech deals worth $20B
Analysts had forecast a blockbuster year for life science M&As, with the tax reforms taking effect and Big Pharma scrambling for late-stage assets. Less than one month in, the predictions seem to be coming true.
-
Pandion raises $58M for its autoimmune platform inspired by the tumor microenvironment
Oncology has long been borrowing lessons from immunology. It may now be time to pay it back. Pandion Therapeutics is tapping into some immune evasion tools observed in cancer to better treat autoimmune and inflammatory disorders.
-
The business case for diversity in life sciences: There just aren’t enough white men to go around
There’s a giant talent void hitting the life sciences and there won’t be enough white men to fill that gap as baby boomers retire in droves.
-
Patents will expire on these medications in 2018
Pinpointing the expiration date of drug patents can make filing taxes look like child’s play. Each drug has wide ranging intellectual property, with timelines that are ever-changing. That said, here’s a list of 26 drugs that will probably go off patent in 2018.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Biopharma watchers arrive at rare consensus: 2018 will be big year for M&A
With the tax reform bill that recently passed and the dramatic rate-cut for overseas cash being repatriated to 14.5 percent from 35 percent, it’s no surprise that M&A deals will abound.
-
In an era of cures, price-prohibitive drugs are an even harder pill to swallow
It’s an incredible time for the life sciences, panelists at a Biotech Showcase session on Monday agreed. However, it comes with a catch: The greater the miracle, the greater the anguish when a patient can’t afford or can’t access the drug.
-
How to woo investors at #JPM18: Stick a needle in their arm
San Diego, California-based Genalyte has spent 10 years developing its lab-on-a-chip technology. Now it’s ready, to try it out on J.P. Morgan investors, quite literally.
-
Does the J.P. Morgan Healthcare Conference really set the tone for year ahead for biopharma?
The J.P. Morgan Healthcare Conference is about so much more than the company presentations. Partnerships are made, deals are signed, and the tone for the biopharma year ahead is set. Or is it?
-
Pfizer and Arvinas sign $830M drug development deal that target proteins causing disease
Pfizer is paying big bucks for yet-to-be-discovered small molecule drugs that can break down harmful proteins in diseases such as cancer and Alzheimer’s.
-
2017 drug approvals: Records, milestones, and controversies
2017 was a blockbuster year for drug approvals, with 46 new molecular entities and some first-of-their-kind gene therapies given the green light. But how much will the new drugs add to the medical armamentarium? And at what cost?
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
